Adolescents

SMILE once-daily regimen non-inferior to triple ART regimen

2023

Findings from the Strategy for Maintenance of HIV suppression with integrase inhibitor + darunavir/ritonavir in children (PENTA-17) trial, simply known as SMILE, were published in eClinicalMedicine on 2 June 2023. SMILE is the first randomised trial to determine whether children living with HIV on ART with suppressed viral load could maintain the suppression on a once-daily regimen compared to the standard of care (SOC) which involves three ART drugs. 

Read More

Adolescents living with HIV from multiple countries being lead-partners in the co-production of research information and findings across global clinical trials

2022

Authors: Cebekhulu, S; Shibemba, M; Conway, M; Kiganda, C; Ahimbisibwe, Bhiri, J; Carter, A; Ely, A; Gondo, S; Nkosi, N.

Presented at: AIDS 2022 and International Workshop on HIV & Adolescence 2022

Read More